Vascular endothelial growth factor pathway’s influence on bevacizumab efficacy in metastatic colorectal cancer treatment  

作　　者：Yuan Qin Fu-Yuan Ma Zhi Zhang Chen-Hao Zhao Biao Huang 

机构地区：[1]College of Life Sciences and Medicine,Zhejiang Sci-Tech University,Hangzhou 310018,Zhejiang Province,China

出　　处：《World Journal of Gastrointestinal Oncology》2024年第11期4514-4517,共4页世界胃肠肿瘤学杂志（英文）

基　　金：The Natural Science Foundation of Zhejiang Province,No.LQ23H050005;The Scientific Research Project of Zhejiang Provincial Education Department,No.Y202250731 and No.Y202353130;China Students’Innovation and Entrepreneurship Training Program,No.202310338044;China Postdoctoral Science Foundation,No.2022M721720.

摘　　要：In this article,an article published in the World Journal of Gastrointestinal Oncology,which focuses on whether the expression of programmed death-ligand 1(PD-L1)affects the effectiveness of chemotherapy regimens,including bevacizumab,in treating patients with colorectal cancer(CRC).Through neutralization of vascular endothelial growth factor(VEGF),bevacizumab inhibits tumor angiogenesis,impairing neovascularization and thereby depriving the tumor of essential nutrients and oxygen.Conversely,PD-L1 binding to VEGF receptor 2 promotes angiogenesis,supporting tumor vasculature.The interplay between these pathways complicates the assessment of bevacizumab’s efficacy in cancer therapy,notably in CRC,where VEGF and PD-L1 significantly affect treatment response.This review examines metastatic CRC treatment strategies,focusing on bevacizumab’s mechanism of action and the role of PD-L1 in this therapeutic context.

关 键 词：BEVACIZUMAB CHEMOTHERAPY Metastatic colorectal cancer PD-1/PD-L1 axis Therapeutic approach Vascular endothelial growth factor 

分 类 号：R735.34[医药卫生—肿瘤]